PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33722946-2 2021 Gout is the most common inflammatory arthritis1, historically poorly managed, and is arguably the only one of the inflammatory arthritides that is curable with appropriate urate-lowering therapy (ULT)2 Whereas febuxostat has been shown to be a more effective ULT3, allopurinol has been the cornerstone of treatment for decades; however, allopurinol is problematic in the elderly, those with renal impairment, and those who carry the HLA-B*5801 antigen who are primarily of Asian origin. Febuxostat 210-220 major histocompatibility complex, class I, B Homo sapiens 433-438 26771445-0 2016 Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. Febuxostat 28-38 major histocompatibility complex, class I, B Homo sapiens 56-61 28957559-9 2017 Conclusion: Routine testing for HLA-B*58:01 in order to reduce the incidence of adverse drug reactions in patients being prescribed allopurinol for gout is unlikely to be cost-effective in the UK; however testing is expected to become cost-effective with reductions in the cost of genotyping, and with the future availability of cheaper, generic febuxostat. Febuxostat 346-356 major histocompatibility complex, class I, B Homo sapiens 32-37 27916277-5 2017 Those who tested positive for HLA-B*5801 received febuxostat. Febuxostat 50-60 major histocompatibility complex, class I, B Homo sapiens 30-35 31308200-0 2019 Febuxostat Desensitization in a Patient with Previous Stevens-Johnson Syndrome and HLA-B*58:01 Genotype. Febuxostat 0-10 major histocompatibility complex, class I, B Homo sapiens 83-88 29642234-7 2018 The evaluation of four models with or without genetic screening and management of allopurinol or febuxostat indicated that the HLA-B*5801 screening had significant cost benefit for clinical management. Febuxostat 97-107 major histocompatibility complex, class I, B Homo sapiens 127-132 26771445-9 2016 CONCLUSIONS: Febuxostat was more effective than allopurinol in reducing the serum urate levels of Han Chinese patients with gout or tophaceous gout who were HLA-B*5801 negative, without causing any serious skin reactions. Febuxostat 13-23 major histocompatibility complex, class I, B Homo sapiens 157-162 26771445-10 2016 Febuxostat should be considered for treatment of Han Chinese patients with gout who are HLA-B*5801 negative. Febuxostat 0-10 major histocompatibility complex, class I, B Homo sapiens 88-93 26365588-1 2015 WHAT IS KNOWN AND OBJECTIVE: Febuxostat is recommended as an alternative drug for gouty patients with a history of allopurinol hypersensitivity or carrying the HLA-B*5801 allele. Febuxostat 29-39 major histocompatibility complex, class I, B Homo sapiens 160-165